Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.

ABSTRACT:

Importance

Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response using tyrosine kinase inhibitors (TKIs) can safely attempt to stop their use. As these medications are very costly, this change in treatment protocols may result in large savings.

Objective

To estimate future savings from attempting to stop TKI use among patients with CML who have deep molecular response.

Design, setting, and participants

A microsimulation model was developed for this decision analytical modeling study to estimate costs for US adults moving from using a TKI, to attempting discontinuation and then reinitiating TKI therapy, if clinically appropriate. Estimates were calculated for US patients who currently have CML and simulated newly diagnosed cohorts of

SUBMITTER: Winn AN 

PROVIDER: S-EPMC10728762 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature